ELIAS JOSEPH JABBOUR to Antigens, CD19
This is a "connection" page, showing publications ELIAS JOSEPH JABBOUR has written about Antigens, CD19.
Connection Strength
1.153
-
Therapy Options in Treating Acute Lymphoblastic Leukemia in Adults. Oncology (Williston Park). 2019 07 16; 33(7).
Score: 0.545
-
Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Am J Hematol. 2023 04; 98(4):666-680.
Score: 0.175
-
A phase 2a, single-arm, open-label study of tafasitamab, a humanized, Fc-modified, anti-CD19 antibody, in patients with relapsed/refractory B-precursor cell acute lymphoblastic leukemia. Cancer. 2021 11 15; 127(22):4190-4197.
Score: 0.157
-
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies. Ann Hematol. 2020 Oct; 99(10):2215-2229.
Score: 0.147
-
Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia. JAMA Oncol. 2018 10 01; 4(10):1413-1420.
Score: 0.129